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Background: Radiofrequency ablation is a minimal invasive therapy in the treatment of bone
metastases. In this study we present a new ablation system enabling an ablation in multiple directions
and with an adaptable size and shape.
Material and methods: VX-2 tumor was used for the induction of experimental bonemetastases in the femur
of six New Zealand white rabbits. X-ray imaging as well as CT and MRI scans before and after treatment was
carried out. After detecting bone tumor, radiofrequency ablation was performed. The ablation instrument
contained a 10 g bipolar, articulated extendable electrode and a proprietary generator with an impedance
controlled algorithm. All bones and the soft tissue were examined histologically.
Results: All animals developed local bone tumor. Mean duration until ﬁrst osteolytic lesions on CT-scans was
48714 days. The mean lesion area was 26mm2. No systemic tumor spread was seen. 6 radiofrequency
procedures were carried out with a mean application time of 6 min72:30 and an average temperature in the
region of effect of 55 1C74. MRI imaging demonstrated an ablation zone of 2376mm around the electrode.
Histopathology showed an extensive heat necrosis with no remaining tumor cells in the ablation area.
Conclusion: Radiofrequency ablation is a quickly developing treatment option on the ﬁeld of minimal invasive
bone tumor therapy. The electrode enables an ablation adapted to size and shape of the metastases. Further
clinical studies are necessary to test and enhance this radiofrequency system.
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bone metastases are one of the most frequent complications of
malignant tumors and they are a relevant source of morbidity. Up to
70% of all tumor patients develop bone metastases [1]. Most of the
patients suffer from pain with a reduction of mobility and life quality
and therefore have a high risk of concomitant complications [2].
Therapy of bone metastases follows three strategies: pain relief,
improvement of mobility and quality of life, and improvement of life
expectancy. Therapeutic possibilities comprise local strategies like
radiation, surgical therapy and systemic therapy. Surgical therapy
needs large approaches and the rate of complications as well as the
comorbidity and length of hospital stay are not negligible. Minimal
invasive therapy of bone tumor is getting more important [3]. The
advantages are obvious. The size of the surgical approach as well as
operation time and complication rate are reduced. Comorbidity,
quality of life and the time as an inpatient are improved [4].
Therefore further developments in the ﬁeld of minimal invasive
tumor therapy are necessary.. This is an open access article un
ry, Department of Orthopaedic
, 55131 Mainz.Radiofrequency ablation in bone tumor is an upcoming tech-
nique which was ﬁrst described by Rosenthal et al. [5]. It is used
to treat multiple benign and malignant diseases. Liver, lung and
bone have become the primary target tissue in the thermal
ablation therapy [6]. Due to its high efﬁcacy and safety, radio-
frequency ablation has become one of the most accepted techni-
ques in hyperthermal ablation therapy [7]. The radiofrequency
system consists of a generator and an electrode system. While the
generators are highly developed, the electrodes for bone ablation
are still the weak point of this technology. They are rigid and
ablate in a predeﬁned and mainly oval shaped zone only. Further
developments are necessary to develop new ablation system with
which a multidirectional ablation is necessary.
In this study we present a new ablation system with which an
ablation in multiple directions and with an adaptable size and
shape of the heat zone is possible.2. Material and Methods
2.1. Animal model
Six female New Zealand white rabbits were used in this trial.
All animals were kept in single cages, had free access to tap waterder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. STAR-system containing the generator and the bipolar navigational ablation
instrument.
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laboratory, the animals were examined and adapted to the
laboratory conditions for one week before entering the study.
All experiments were approved by the governmental Animal
Ethics Committee.
A VX-2 tumor suspension (Cell Line Service, Eppelheim,
Germany) as well as a three-dimensional matrix carrying the
suspension were used in this trial. The matrix consists of alginate.
For preparation of the spheroids an alginate solution was mixed
by solving 1% of alginate powder (Roth, Germany) in DMEM high
glucose (BD, Germany) under stirring for 30 min. After ﬁnishing,
the alginate solution was mixed in ratio 1:1 with 500 ml of
VX-2 tumor suspension. Tumor cell spheroids were created by
dropping 1 ml of this mixture in a 10% calcium chloride solution
(Braun, Germany). 25 spheroids were produced out of 1 ml
of the mixture. 5 of these spheroids were implanted into the left
distal femoral metaphysis of the rabbits by a minimal invasive
approach.
All procedures were performed under general anesthesia using
50 mg/kg body weight of ketamine hydrochloride s.c. (Parker-
Davis, Berlin, Germany) and 25 mg/kg body weight of 2% xylazine
hydrochloride (Bayer, Leverkusen, Germany). After careful disin-
fection and preparation of the knee- and leg-area, a small long-
itudinal medial and infrapatellar skin incision was carried out.
The patellar tendon was splitted longitudinally. Under ﬂuoro-
scopy guidance a cannula was introduced into the left metaphysis
of the femoral leg. After preparing the femoral bone, the implan-
tation of the tumor cells was carried out, using 5 alginate
spheroids for each animal. The spheroids were introduced
through the cannula using a blunt trocar. After this procedure,
the cannula was pulled back and bone wax was introduced in
order to seal the drill hole and to prevent a leakage of tumor cells
into the soft tissue. After ﬁnishing the implantation the soft tissue
was reconstructed surgically.
2.2. Radiofrequency ablation
Radiofrequency ablation was carried out in all animals. The
STAR-system (Spinal Tumor Ablation with Radiofrequency; Dﬁne,
San Jose, CA, U.S.) was used in this trial. The STAR-system contains
a generator and a bipolar navigational ablation instrument
(Fig. 1). The ablation generator has a bipolar design with tem-
perature sensing and controlled energy delivery. The ablation
electrode has a new navigational concept and enables a multi-
directional positioning of the tip of the electrode. This provides a
site speciﬁc access to the bone. All animals were screened for
metastases using CT- and MRI-scans. The changes in the peri-
meter (mm) and the area of osteolytic bone (mm2) were eval-
uated subsequently. Radiofrequency ablation was carried out
after detecting bone metastases with a tumor size bigger than
10 mm in diameter. The knee joint was opened using the same
surgical approach as for the implantation of the tumor cells.
The radiofrequency electrode (10 G) was positioned under CT-
guidance. The handgrip consists of three separate grips for the
positioning of the electrode. The rotatable blue handgrip turns the
whole instrument with a range of rotation of up to 3601.
The rotatable gray grip enables a bending of the electrode of up
to 901 while the white grip changes the active length of the tip of
the electrode. Radiofrequency ablation was carried out using the
bipolar radiofrequency generator (Fig. 1).
2.3. Postinterventional assessments
All animals were examined before and after radiofrequency
ablation using CT- (Siemens Somatom, Germany, UHR-spine
program) and MRI scans (Siemens Symphony, Germany, handwrist coil, T1/ T2 weighted and fat suppressed imaging, contrast
enhanced sequences). Tumor size as well as shape and size of the
ablation necrosis was measured. Before ﬁnishing the trial, all
animals were scanned for a systemic tumor spread using CT. After
ﬁnishing the ablation procedure and the imaging all animals were
sacriﬁced. Both the femora were collected for histopathological
examination.3. Results
3.1. Experimental bone tumor
6 animals were treated. Inoculation of tumor cells was well
tolerated as animals recovered quickly from the surgical proce-
dure. General anesthesia was carried out without any side effects.
There were no restrictions in the mobility of the operated knee in
all animals. The mean time of the surgical procedure was 6 min.
5 spheroids were implanted in the distal femur of each animal.
The drill hole was sealed using bone wax. There were no technical
and post procedural complications. All animals developed local
bone tumor. Lytic lesions were detected by X-ray in some animals
as early as 4 weeks after tumor cell implantation. Mean duration
until ﬁrst osteolytic lesions on CT-scans was 48714 day.
The mean lesion area on ﬁrst detection was 26 mm2. No systemic
tumor spread was seen in all animals.3.2. Radiological examination
CT and MRI scans were carried out in general anesthesia before
and after the ablation procedure (Fig. 2). Radiofrequency ablation
was carried out CT-guided. MRI imaging demonstrated a well
conﬁned ablation zone of 2376 mm around the active length of
Fig. 2. Sagittal CT reconstruction of the femur of a rabbit. See the tumor with a
local destruction in the distal femur marked with an arrow.
Fig. 3. Sagittal MRI scans of the femoral bone with a tumor growth distally, on the le
growth on the left side (arrow) as well as the extensive necrosis and the remaining tu
Fig. 4. Histopathological examination. Left side: hematoxylin-eosin stain, light micros
arrow). Remaining tumor tissue with tumor cells at the edge of the necrosis (upper arrow
channel (red marked). Remaining tumor tissue (green marked). (For interpretation of th
of this article.)
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before and after the ablation.
3.3. Radiofrequency ablation
Tumors41 cm in diameter received CT guided radiofrequency
ablation using the STAR System. The ablation instrument con-
tained a 10 g bipolar, articulated extendable electrode containing
multiple thermocouples and a proprietary generator with impe-
dance and temperature controlled algorithm. 6 procedures were
carried out with a mean application time of 6 min72:30 and an
average temperature in the region of effect (distal thermocouple)
of 55 1C74. Tumor coagulation was ﬁnished when the continuing
energy-ﬂow was stopped due to an arising of the impedance or
reaching a temperature of more than 45 1C in the proximal
thermocouple. The proximal thermocouple is an important safety
marker that the treatment is conﬁned within the targeted area.
Radiofrequency ablation was carried successfully and without
complications in all animals.
3.4. Histology
The femora were collected for histopathological examination.
All animals developed local bone metastases in the distal femur.
The area around the former drill hole showed an extensive tumor
inﬁltration with a circular necrosis after thermal ablation. In theft side before and on the right side after the ablation procedure. Note the tumor
mor tissue around the ablation zone on the right side (arrow).
copy. Circular heat necrosis around the insertion channel of the electrode (lower
) Right side: Cutted preparation of a rabbit leg. Heat necrosis around the insertion
e references to color in this ﬁgure legend, the reader is referred to the web version
D. Proschek et al. / Journal of Bone Oncology 1 (2012) 63–6666area of the necrosis no tumor cells were detected. Remaining
tumor cells were found at the edge of the coagulation zone
(Fig. 4).4. Discussion
Radiofrequency ablation has a long history of use. It has been
used especially in the neurosurgical ﬁeld [8,9]. Rosenthal
described the ﬁrst ablations in bone 20 years ago [5]. Technically
the radiofrequency generator forms an electric current leading to
an ionic agitation in the tissue creating heat. The energy leads to
cell death and coagulation necrosis. Radiofrequency ablation has
several advantages: it is a minimal invasive therapy, major
complications are unknown [6]. The energy application can be
controlled by the applicator and generator design. Impedance
measurements allow an exact thermal ablation of pathologic
tissue. However radiofrequency ablation is used as a palliative
therapy in bone metastases/ bone tumor patients [6,10]. Actually
osteoid osteoma is the only bone tumor which can be treated by
ablation following a curative approach [11,12].
Another limitation of radiofrequency therapy is that available
electrodes are rigid and unidirectional. This reduces the size and
shape of a possible ablation zone signiﬁcantly. Bone metastases have
a variable shape and to treat the metastases completely would
presume to completely destroy tumor tissue without interfering with
healthy tissue. The available electrodes only provide a limited
ablation with predeﬁned size and shape of the ablation zone. This
is the main reason why radiofrequency ablation does not follow a
curative approach in the treatment of bone metastases. A change in
design and functionality of the electrodes could help to change this
approach. A possible way is to use a multidimensional ablating
RF-electrode which is presented here.
The ablation instrument which was used in this study contained a
bipolar, articulated extendable electrode with multiple thermocou-
ples and a proprietary generator (Fig. 1). The electrode provides a site
speciﬁc and controllable ablation. The possibility to articulate and
extend the electrode enables to follow a preoperatively planned
ablation scheme. In this study all ablation procedures were carried
out sufﬁciently and without complications. The electrodes were
positioned CT-guided. After introducing into the bone, the active
length of the electrode was positioned in the center of the tumor
tissue using articulation and extension of the instrument.
A possible disadvantage of the electrode is that there is no
feedback regarding the extent and the shape of the heat necrosis.
In the CT or X-ray scan during the intervention the change of the
heat reaction cannot be displayed [13]. Therefore the precision of
the electrode is not sufﬁcient to enable a curative treatment of the
metastases. The setup of the procedure with the preoperative
planning and the intraoperative guided positioning of the elec-
trode is complex. But the design of the instrument is a step in the
right direction offering variable opportunities in the treatment of
bone metastases. Especially automation might be possible with
this electrode using a CT data set for planning and enabling a
complete ablation of the metastases.
The animal model used in this trial enabled a reproducible
induction of local bone tumor. The spheroids were stable and big
enough to be inserted in the rabbit femur. They additionally pre-
vented the tumor cells from being washed out into the body inducing
a systemic tumor spread. All procedures were carried out without
complications. A CT scan of the whole body showed no systemic
spread. The mean tumor size was 26mm2 and big enough for testing
radiofrequency ablation sufﬁciently. MRI scans before and after the
radiofrequency ablation are essential to evaluate tissue changes of the
thermal ablation before and after the intervention. In this study MRI
after the ablation showed a heat necrosis of 2376mm in size withremaining tumor tissue around the necrosis. MRI during the inter-
vention is not possible due to the design of the RF system. Changes of
the tissue cannot be displayed during the ablation.
The study presented here has two disadvantages: the results of
this animal trial cannot be transferred to clinical conditions readily
and the animals were sacriﬁced after the radiofrequency ablation.
Data would have been more detailed if the animals would have
survived the procedure and another MRI scan would have been taken
e.g. 1 week after the ablation. This was not possible due to the
standards of our Ethical Committee. Rabbits were used in this study
because the bone composition and density is nearly similar to human
bone [14]. They are the most commonly used animals for medical
research [15]. Bones of small animals like rats or mice are not optimal
to sufﬁciently evaluate surgical techniques due to limited size and
different microstructure [16]. VX-2 carcinoma was used in this trial
because it is the only bone tumor available for rabbits.
The small sample size is a limitation of this study and further
examinations are necessary. The results of this animal trial are
promising and a clinical multicenter trial is planned based on the
preclinical data.5. Conclusions
Radiofrequency ablation is a quickly developing treatment
option on the ﬁeld of minimal invasive bone tumor therapy. With
the articulated extendable electrode presented here it is possible
to carry out radiofrequency ablation in multiple directions. The
electrode enables an ablation adapted to size and shape of the
metastases. Further clinical studies are necessary to test and
enhance this radiofrequency system.References
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